Collaboration Between the Paul Scherrer Institut and Vitalea Science Brings Compact Accelerator Mass Spectrometer to the Pharmaceutical Industry

Share Article

The Bio-MICADAS is a next-generation, high throughput AMS instrument designed to meet the specific needs of clinical research. It was developed through a collaboration between the Paul Scherrer Institut of Zurich, Switzerland and Vitalea to meet strict clinical requirements for drug development. It provides several new options for clinical drug development such as Phase 0 microdosing and Phase 1 ADME without radioactivity.

2007, a compact atom counter will be available to drug developers for microdosing-based clinical analyses.

The Bio-MICADAS is a next-generation, high throughput AMS instrument designed to meet the specific needs of clinical research. It was developed through a collaboration between the Paul Scherrer Institut of Zurich, Switzerland and Vitalea to meet strict requirements for improving drug development.

The instrument is a significant milestone in pharmaceutical development. It is anticipated to spark growth in Phase 0 microdosing and microdose/Phase 1 clinical trials to test key drug performance characteristics directly in humans. Microdosing is a relatively new concept that promises to reduce reliance on laboratory animals for drug selection by enabling early screening tests safely in people. While endorsed by both US and European regulatory agencies, enthusiasm for microdosing has been tempered by the complexity and difficult operation of current supporting technology. The new Bio-MICADAS was specifically designed to overcome these difficulties with an instrument that is compact and easier to use and maintain in clinical environments.

"It is a great pleasure and honor to work with researchers at the Paul Scherrer Institut (PSI) to develop an instrument that is custom designed for biomedical sciences. PSI researchers are the world experts in particle accelerator design, and they have brought an unparalleled expertise to a new instrument designed for biomedical applications," commented Dr. Stephen Dueker, President of Vitalea. "We believe this technology will streamline clinical drug development in many ways."

Dr. Hans-Arno Synal of the PSI led development of the Bio-MICADAS and commented that "The collaboration with Vitalea has brought a new biomedical perspective to our research that underscores the value of collaborations between our research institute and industry for enhancing scientific applications in a wide range of industries--particularly pharmaceutical and biotechnology development. We believe this tool will bring important drugs more efficiently to market and we are very proud that a team of physicists will have a chance to impact global health in such a direct way."

About Vitalea Science (http://www.vitaleascience.com)

Vitalea Science is a leading contract research organization that provides ultra-sensitive detection strategies for drugs and drug candidates at microdose levels. Situated in Northern California, the company was formed by chemists and physicists from the University of California and the Department of Energy's Lawrence Livermore National Laboratory in 2003.

About Paul Scherrer Institut (http://www.psi.ch/index_e.shtml)

The Paul Scherrer Institut is the largest Swiss national research institute with approximately 1,200 members on staff. PSI develops and manages complex research programs that integrate high standards of know-how, experience and professionalism. It is one of the world's leading user laboratories for the national and international scientific community. Through its research, PSI acquires new basic knowledge and actively pursues its application to industry.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

STEPHEN DUEKER
Visit website